Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Insmed's interest expense for the
three
months ended in Mar. 2026 was € -16.2 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was €-65.8 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Insmed's Operating Income for the
three
months ended in Mar. 2026 was € -173.2 Mil. Insmed's Interest Expense for the
three
months ended in Mar. 2026 was € -16.2 Mil.
Insmed did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Insmed's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as
Insmed did not have earnings to cover the interest expense.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Insmed Interest Expense Historical Data
* Premium members only.
The historical data trend for Insmed's Interest Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-65.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Insmed (MIL:1INSM) has a Interest Expense of €-65.8 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Insmed and its competitors.
Is Insmed's Interest Expense too high?
Insmed's current Interest Expense is €-65.8 Mil. Overall, Insmed has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Insmed's Interest Expense compare to INCY and BNTX?
Insmed's Interest Expense of €-65.8 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Insmed and its competitors. Insmed's current Interest Expense is €-65.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Insmed stock overvalued right now?
Based on GuruFocus' analysis, Insmed (MIL:1INSM) is currently considered Possible Value Trap. The stock's GF Value™ is €160.63, compared to a current price of €86.10 — trading 46.4% below its estimated fair value. The current Interest Expense is €-65.8 Mil. Insmed's overall GF Score™ is 45/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Insmed (MIL:1INSM), the current Interest Expense is €-65.8 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Insmed (MIL:1INSM) Overvalued in 2026?
Based on GuruFocus' analysis, Insmed stock appears to be undervalued.
The current stock price of €86.10 is trading 46.4% below its estimated GF Value™ of €160.63.
GuruFocus considers Insmed to be Possible Value Trap.
Key valuation signals for MIL:1INSM:
Interest Expense: €-65.8 Mil
GF Value™: €160.63 vs. price of €86.10 (46.4% below fair value)
No single metric tells the full story. See the MIL:1INSM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
45GF Score
Get the complete analysis for MIL:1INSM
Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:1INSM has been successfully added to your 
